← Back to Search

Cancer Vaccine

SBT777101 Dose Level 2 for Hidradenitis Suppurativa

Phase 1

Recruiting

Research Sponsored by Sonoma Biotherapeutics, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up day of treatment to end of follow-up period (48 weeks)

Awards & highlights

Study Summary

This trial will test a new drug, SBT777101, in people with hidradenitis suppurativa. The drug will be given in increasing doses to test its safety and effects.

Who is the study for?

This trial is for individuals with Hidradenitis Suppurativa, a skin condition characterized by painful lumps under the skin. Participants must meet certain health criteria to join, but specific inclusion and exclusion details are not provided.Check my eligibility

What is being tested?

The study is testing SBT777101, a new treatment given as a single dose to people with Hidradenitis Suppurativa. The trial will start at lower doses and increase only if those are shown to be safe.See study design

What are the potential side effects?

Since this is an early-stage trial for SBT777101, potential side effects aren't listed here. Generally, such trials monitor for any adverse reactions ranging from mild symptoms like headaches or nausea to more serious ones.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ day of treatment to end of follow-up period (48 weeks)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~day of treatment to end of follow-up period (48 weeks)

This trial's timeline: 3 weeks for screening, Varies for treatment, and day of treatment to end of follow-up period (48 weeks) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Incidence and nature of Dose Limiting Toxicities [DLTs]

Incidence, nature, and severity of adverse events [Safety and Tolerability]

Trial Design

3Treatment groups

Experimental Treatment

Group I: SBT777101 Dose Level 3Experimental Treatment1 Intervention

High dose SBT777101

Group II: SBT777101 Dose Level 2Experimental Treatment1 Intervention

Mid dose SBT777101

Group III: SBT777101 Dose Level 1Experimental Treatment1 Intervention

Low dose SBT777101

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Sonoma Biotherapeutics, Inc.Lead Sponsor

2 Previous Clinical Trials

64 Total Patients Enrolled

Mark Eisner, MDStudy DirectorSonoma Biotherapeutics, Inc.

1 Previous Clinical Trials

24 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are patients currently able to enroll in this ongoing clinical trial?

"Indeed, the details on clinicaltrials.gov affirm that patient enrollment is ongoing for this investigation. The trial was initially listed on May 1st, 2024 and underwent its latest update on April 8th, 2024. A total of 24 participants are sought from a single site."

Answered by AI

May I inquire about the criteria for potential participation in this medical study?

"To participate in this study, individuals must be aged between 18 and 70 years old and have a diagnosis of hidradenitis suppurativa. The trial is currently open to approximately 24 eligible participants."

Answered by AI

Is this medical research open to individuals who have surpassed the age of 35?

"Enrollment for this research study is open to individuals aged over 18 and under 70 years."

Answered by AI

What is the number of participants currently enrolled in this clinical study?

"Indeed, the details on clinicaltrials.gov imply that this research study is presently enrolling volunteers. Initially shared on May 1st, 2024, and most recently revised on April 8th, 2024, this trial aims to enroll a total of 24 participants from one designated site."

Answered by AI